Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for Immunome (IMNM) over the last 3 years, with Q1 2025 value amounting to $4.0 million.

  • Immunome's Current Deferred Revenue fell 6849.74% to $4.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $4.0 million, marking a year-over-year decrease of 6849.74%. This contributed to the annual value of $6.9 million for FY2024, which is 3385.11% down from last year.
  • Immunome's Current Deferred Revenue amounted to $4.0 million in Q1 2025, which was down 6849.74% from $6.9 million recorded in Q4 2024.
  • In the past 5 years, Immunome's Current Deferred Revenue ranged from a high of $18.2 million in Q1 2023 and a low of $4.0 million during Q1 2025
  • For the 3-year period, Immunome's Current Deferred Revenue averaged around $12.1 million, with its median value being $12.6 million (2024).
  • Per our database at Business Quant, Immunome's Current Deferred Revenue plummeted by 2874.69% in 2024 and then tumbled by 6849.74% in 2025.
  • Quarter analysis of 3 years shows Immunome's Current Deferred Revenue stood at $10.5 million in 2023, then tumbled by 33.85% to $6.9 million in 2024, then tumbled by 42.16% to $4.0 million in 2025.
  • Its Current Deferred Revenue was $4.0 million in Q1 2025, compared to $6.9 million in Q4 2024 and $9.7 million in Q3 2024.